ReviewHealth science reports2026
Prevalence, Incidence, and Impact of Cancer in Atrial Fibrillation: A Systematic Review and Meta-Analysis of 70,000,000 Patients.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Contemporary studies indicate that atrial fibrillation (AF) is common in patients with cancer and adversely affects their prognosis. AF and cancer also share several risk factors. Nevertheless, the prevalence, incidence, and overall impact of cancer in patients with AF are not well defined. This study was designed to estimate the prevalence and incidence of cancer in an AF population and to evaluate its effect on clinical outcomes. Methods: A systematic review and meta-analysis were performed following international guidelines. We searched PubMed, Web of Science, Embase, and Cochrane Library for studies reporting the prevalence and incidence of cancer in patients with AF. Data were extracted from the included studies and pooled using a random-effects model. Results: The overall prevalence of cancer among AF patients was 1141.01 per 10,000 (95% CI: 975.43-1330.56; 95% PI: 219.37-4251.57), with an incidence of 172.22 per 10,000 person-years (95% CI: 127.76-232.15; 95% PI: 40.32-735.69). Both prevalence and incidence varied according to cancer type, patient gender, and comorbid conditions. Cancer was associated with a significantly increased risk of all-cause mortality (OR: 1.83, 95% CI: 1.60-2.08) and bleeding (OR: 1.62, 95% CI: 1.37-1.92). No significant associations were observed for cardiovascular death or stroke/systemic embolism. Conclusions: Cancer is common in AF patients, affecting approximately 11% of this population. In addition, the incidence of cancer in AF patients is substantial and should not be overlooked. Cancer is associated with worse clinical outcomes in AF patients, including a more than 1.8-fold increased risk of all-cause mortality and 1.6-fold increased risk of bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.